Results 51 to 56 of about 917 (56)

Cockayne syndrome mice reflect human kidney disease and are defective in de novo NAD biosynthesis. [PDF]

Cell Death Differ
Pekhale K, Tiwari V, Hussain M, Bridges CC, Croteau DL, Levi M, Rosenberg AZ, Santo B, Yang X, Kulikowicz T, Wang XX, Lee JH, Bohr VA.   +12 more
europepmc   +1 more source

NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. [PDF]

Mol Cancer Res
Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS.   +16 more
europepmc   +1 more source

Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis. [PDF]

J Transl Med
Ho YK, Woo JY, Loke KM, Deng LW, Too HP.
europepmc   +1 more source

CAZac: an activity descriptor for carbohydrate-active enzymes. [PDF]

Nucleic Acids Res
Lombard V, Henrissat B, Garron ML.
europepmc   +1 more source

Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study. [PDF]

BMC Neurol
Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews KD, Weihl CC, Wicklund M, Hung M, Statland J, Johnson NE, GRASP-LGMD Consortium.   +11 more
europepmc   +1 more source

Degradation of [3H]thymidine by a pentosyltransferase (EC 2.4.2.4) in the plasma of man and different animals

Experientia, 1977
[3H]Thymidine is degraded by an enzyme (thymidine phosphorylase; EC 2.4.2.4) which we have identified in the plasma of man and some animals. The presence of this enzyme in plasma or sera used to supplement culture media may, under certain experimental conditions, limit the validity of measuring the uptake of radiolabeled thymidine as a means of ...
J L, Pauly, M G, Schuller, A A, Zelcer, M J, Germain   +3 more
openaire   +2 more sources